BACKGROUND: Suicide gene therapy for malignant gliomas has shown encouraging results in the latest clinical trials. However, prodrug application was most often restricted to short-term treatment (14 days), especially when replication-defective vectors were used. We previously showed that a substantial fraction of herpes simplex virus thymidine kinase (HSV-TK) transduced tumor cells survive ganciclovir (GCV) treatment in an orthotopic glioblastoma (GBM) xenograft model. Here we analyzed whether these TK+ tumor cells are still sensitive to prodrug treatment and whether prolonged prodrug treatment can enhance treatment efficacy. METHODS: Glioma cells positive for TK and green fluorescent protein (GFP) were sorted from xenograft tumors recurring after suicide gene therapy, and their sensitivity to GCV was tested in vitro. GBM xenografts were treated with HSV-TK/GCV, HSV-TK/valganciclovir (valGCV), or HSV-TK/valGCV + erlotinib. Tumor growth was analyzed by MRI, and survival as well as morphological and molecular changes were assessed. RESULTS: TK-GFP+ tumor cells from recurrent xenograft tumors retained sensitivity to GCV in vitro. Importantly, a prolonged period (3 mo) of prodrug administration with valganciclovir (valGCV) resulted in a significant survival advantage compared with short-term (3 wk) application of GCV. Recurrent tumors from the treatment groups were more invasive and less angiogenic compared with primary tumors and showed significant upregulation of epidermal growth factor receptor (EGFR) expression. However, double treatment with the EGFR inhibitor erlotinib did not increase therapeutic efficacy. CONCLUSION: Long-term treatment with valGCV should be considered as a replacement for short-term treatment with GCV in clinical trials of HSV-TK mediated suicide gene therapy.
BACKGROUND: Suicide gene therapy for malignant gliomas has shown encouraging results in the latest clinical trials. However, prodrug application was most often restricted to short-term treatment (14 days), especially when replication-defective vectors were used. We previously showed that a substantial fraction of herpes simplex virus thymidine kinase (HSV-TK) transduced tumor cells survive ganciclovir (GCV) treatment in an orthotopic glioblastoma (GBM) xenograft model. Here we analyzed whether these TK+ tumor cells are still sensitive to prodrug treatment and whether prolonged prodrug treatment can enhance treatment efficacy. METHODS:Glioma cells positive for TK and green fluorescent protein (GFP) were sorted from xenograft tumors recurring after suicide gene therapy, and their sensitivity to GCV was tested in vitro. GBM xenografts were treated with HSV-TK/GCV, HSV-TK/valganciclovir (valGCV), or HSV-TK/valGCV + erlotinib. Tumor growth was analyzed by MRI, and survival as well as morphological and molecular changes were assessed. RESULTS: TK-GFP+ tumor cells from recurrent xenograft tumors retained sensitivity to GCV in vitro. Importantly, a prolonged period (3 mo) of prodrug administration with valganciclovir (valGCV) resulted in a significant survival advantage compared with short-term (3 wk) application of GCV. Recurrent tumors from the treatment groups were more invasive and less angiogenic compared with primary tumors and showed significant upregulation of epidermal growth factor receptor (EGFR) expression. However, double treatment with the EGFR inhibitor erlotinib did not increase therapeutic efficacy. CONCLUSION: Long-term treatment with valGCV should be considered as a replacement for short-term treatment with GCV in clinical trials of HSV-TK mediated suicide gene therapy.
Authors: Naomi P O'Grady; Mary Alexander; Lillian A Burns; E Patchen Dellinger; Jeffrey Garland; Stephen O Heard; Pamela A Lipsett; Henry Masur; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne G Randolph; Mark E Rupp; Sanjay Saint Journal: Clin Infect Dis Date: 2011-04-01 Impact factor: 9.079
Authors: Z Ram; K W Culver; E M Oshiro; J J Viola; H L DeVroom; E Otto; Z Long; Y Chiang; G J McGarrity; L M Muul; D Katz; R M Blaese; E H Oldfield Journal: Nat Med Date: 1997-12 Impact factor: 53.440
Authors: Olivier Keunen; Mikael Johansson; Anaïs Oudin; Morgane Sanzey; Siti A Abdul Rahim; Fred Fack; Frits Thorsen; Torfinn Taxt; Michal Bartos; Radovan Jirik; Hrvoje Miletic; Jian Wang; Daniel Stieber; Linda Stuhr; Ingrid Moen; Cecilie Brekke Rygh; Rolf Bjerkvig; Simone P Niclou Journal: Proc Natl Acad Sci U S A Date: 2011-02-14 Impact factor: 11.205
Authors: Krishna M Talasila; Anke Soentgerath; Philipp Euskirchen; Gro V Rosland; Jian Wang; Peter C Huszthy; Lars Prestegarden; Kai Ove Skaftnesmo; Per Øystein Sakariassen; Eskil Eskilsson; Daniel Stieber; Olivier Keunen; Narve Brekka; Ingrid Moen; Janice M Nigro; Olav K Vintermyr; Morten Lund-Johansen; Simone Niclou; Sverre J Mørk; Per Oyvind Enger; Rolf Bjerkvig; Hrvoje Miletic Journal: Acta Neuropathol Date: 2013-02-22 Impact factor: 17.088
Authors: Tiago Ferreira; Amit Kulkarni; Clemens Bretscher; Petr V Nazarov; Jubayer A Hossain; Lars A R Ystaas; Hrvoje Miletic; Ralph Röth; Beate Niesler; Antonio Marchini Journal: Viruses Date: 2022-05-11 Impact factor: 5.818
Authors: Justin V Joseph; Capucine R Magaut; Simon Storevik; Luiz H Geraldo; Thomas Mathivet; Md Abdul Latif; Justine Rudewicz; Joris Guyon; Matteo Gambaretti; Frida Haukas; Amalie Trones; Lars A Rømo Ystaas; Jubayer A Hossain; Sandra Ninzima; Sylvain Cuvellier; Wenjing Zhou; Tushar Tomar; Barbara Klink; Lalit Rane; Bronwyn K Irving; Joanne Marrison; Peter O'Toole; Heiko Wurdak; Jian Wang; Zhang Di; Even Birkeland; Frode S Berven; Frank Winkler; Frank A E Kruyt; Andreas Bikfalvi; Rolf Bjerkvig; Thomas Daubon; Hrvoje Miletic Journal: Neuro Oncol Date: 2022-04-01 Impact factor: 12.300
Authors: Amit Kulkarni; Tiago Ferreira; Clemens Bretscher; Annabel Grewenig; Nazim El-Andaloussi; Serena Bonifati; Tiina Marttila; Valérie Palissot; Jubayer A Hossain; Francisco Azuaje; Hrvoje Miletic; Lars A R Ystaas; Anna Golebiewska; Simone P Niclou; Ralf Roeth; Beate Niesler; Amélie Weiss; Laurent Brino; Antonio Marchini Journal: Nat Commun Date: 2021-06-22 Impact factor: 14.919
Authors: Cristina Barca; Christoph M Griessinger; Andreas Faust; Dominic Depke; Markus Essler; Albert D Windhorst; Nick Devoogdt; Kevin M Brindle; Michael Schäfers; Bastian Zinnhardt; Andreas H Jacobs Journal: Pharmaceuticals (Basel) Date: 2021-12-22